The US FDA has expanded the approval of evinacumab-dgnb (Evkeeza) to include patients aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). The drug, which inhibits lipoprotein lipase and endothelial lipase, showed a significant reduction in LDL-cholesterol levels in a study of 20 patients in this age group. Safety and efficacy data were similar to those in older patients with HoFH.
In un'altra lingua
dal contenuto originale
www.medscape.com
Approfondimenti chiave tratti da
by Steve Stiles alle www.medscape.com 03-22-2023
https://www.medscape.com/viewarticle/990016Domande più approfondite